Seres Therapeutics (MCRB) Competitors

Seres Therapeutics (NASDAQ:MCRB) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Does the MarketBeat Community prefer MCRB or CRVO?

Seres Therapeutics received 519 more outperform votes than CervoMed when rated by MarketBeat users. However, 100.00% of users gave CervoMed an outperform vote while only 72.40% of users gave Seres Therapeutics an outperform vote.

Company	Underperform	Outperform
Seres Therapeutics	Outperform Votes 522 72.40%	Underperform Votes 199 27.60%
CervoMed	Outperform Votes 3 100.00%	Underperform Votes No Votes

Which has more risk and volatility, MCRB or CRVO?

Seres Therapeutics has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, CervoMed has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.

Do insiders and institutionals hold more shares of MCRB or CRVO?

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 5.1% of Seres Therapeutics shares are owned by company insiders. Comparatively, 2.0% of CervoMed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has better earnings and valuation, MCRB or CRVO?

CervoMed has lower revenue, but higher earnings than Seres Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$126.33M	0.90	-$113.72M	-$0.90	-0.83
CervoMed	$7.14M	21.08	-$2.17M	N/A	N/A

Do analysts prefer MCRB or CRVO?

Seres Therapeutics currently has a consensus price target of $6.50, indicating a potential upside of 767.36%. CervoMed has a consensus price target of $57.50, indicating a potential upside of 135.75%. Given Seres Therapeutics' higher probable upside, research analysts clearly believe Seres Therapeutics is more favorable than CervoMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
CervoMed	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is MCRB or CRVO more profitable?

Seres Therapeutics' return on equity of 0.00% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	N/A	-32.43%
CervoMed	N/A	-18.31%	-15.48%

Does the media prefer MCRB or CRVO?

In the previous week, Seres Therapeutics had 8 more articles in the media than CervoMed. MarketBeat recorded 9 mentions for Seres Therapeutics and 1 mentions for CervoMed. CervoMed's average media sentiment score of 1.82 beat Seres Therapeutics' score of 0.07 indicating that CervoMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CervoMed	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Seres Therapeutics beats CervoMed on 8 of the 13 factors compared between the two stocks.